Hims & Hers Health Competitors

Hims & Hers Health (NYSE:HIMS) and Coursera (NASDAQ:COUR) are both mid-cap consumer defensive companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Valuation and Earnings

This table compares Hims & Hers Health and Coursera's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Hims & Hers Health and Coursera's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Hims & Hers Health and Coursera, as provided by MarketBeat.

Hims & Hers Health currently has a consensus price target of $16.20, suggesting a potential upside of 41.11%. Coursera has a consensus price target of $51.6667, suggesting a potential upside of 22.99%. Given Hims & Hers Health's higher possible upside, research analysts clearly believe Hims & Hers Health is more favorable than Coursera.

Summary

Coursera beats Hims & Hers Health on 2 of the 3 factors compared between the two stocks.

AppHarvest (NASDAQ:APPH) and Hims & Hers Health (NYSE:HIMS) are both consumer defensive companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for AppHarvest and Hims & Hers Health, as provided by MarketBeat.

AppHarvest presently has a consensus target price of $42.00, suggesting a potential upside of 190.26%. Hims & Hers Health has a consensus target price of $16.20, suggesting a potential upside of 41.11%. Given AppHarvest's stronger consensus rating and higher probable upside, equities analysts clearly believe AppHarvest is more favorable than Hims & Hers Health.

Profitability

This table compares AppHarvest and Hims & Hers Health's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares AppHarvest and Hims & Hers Health's revenue, earnings per share (EPS) and valuation.

Summary

AppHarvest beats Hims & Hers Health on 2 of the 3 factors compared between the two stocks.

Hims & Hers Health (NYSE:HIMS) and 17 Education & Technology Group (NYSE:YQ) are both consumer defensive companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Valuation and Earnings

This table compares Hims & Hers Health and 17 Education & Technology Group's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Hims & Hers Health and 17 Education & Technology Group's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for Hims & Hers Health and 17 Education & Technology Group, as provided by MarketBeat.com.

Hims & Hers Health currently has a consensus price target of $16.20, indicating a potential upside of 41.11%. 17 Education & Technology Group has a consensus price target of $21.00, indicating a potential upside of 250.58%. Given 17 Education & Technology Group's stronger consensus rating and higher probable upside, analysts plainly believe 17 Education & Technology Group is more favorable than Hims & Hers Health.

Summary

17 Education & Technology Group beats Hims & Hers Health on 2 of the 2 factors compared between the two stocks.

Hims & Hers Health (NYSE:HIMS) and First High-School Education Group (NYSE:FHS) are both consumer defensive companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Hims & Hers Health and First High-School Education Group's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Hims & Hers Health and First High-School Education Group's top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Hims & Hers Health and First High-School Education Group, as provided by MarketBeat.

Hims & Hers Health presently has a consensus price target of $16.20, suggesting a potential upside of 41.11%. Given Hims & Hers Health's higher possible upside, analysts plainly believe Hims & Hers Health is more favorable than First High-School Education Group.

Summary

Hims & Hers Health beats First High-School Education Group on 2 of the 3 factors compared between the two stocks.

Meat-Tech 3D (NASDAQ:MITC) and Hims & Hers Health (NYSE:HIMS) are both consumer defensive companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.

Earnings and Valuation

This table compares Meat-Tech 3D and Hims & Hers Health's revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Meat-Tech 3D and Hims & Hers Health, as provided by MarketBeat.

Hims & Hers Health has a consensus target price of $16.20, suggesting a potential upside of 41.11%. Given Hims & Hers Health's higher probable upside, analysts plainly believe Hims & Hers Health is more favorable than Meat-Tech 3D.

Profitability

This table compares Meat-Tech 3D and Hims & Hers Health's net margins, return on equity and return on assets.

Summary

Hims & Hers Health beats Meat-Tech 3D on 2 of the 2 factors compared between the two stocks.

The Alkaline Water (NYSE:WTER) and Hims & Hers Health (NYSE:HIMS) are both consumer defensive companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Valuation and Earnings

This table compares The Alkaline Water and Hims & Hers Health's revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current recommendations for The Alkaline Water and Hims & Hers Health, as reported by MarketBeat.

Hims & Hers Health has a consensus target price of $16.20, suggesting a potential upside of 41.11%. Given Hims & Hers Health's higher possible upside, analysts clearly believe Hims & Hers Health is more favorable than The Alkaline Water.

Profitability

This table compares The Alkaline Water and Hims & Hers Health's net margins, return on equity and return on assets.